AI Engines For more Details: Perplexity Kagi Labs You
Antiparasitic Activity: Carbarsone has been historically used as an antiparasitic agent in veterinary medicine, particularly for the treatment of coccidiosis, a protozoal infection that affects the intestinal tract of livestock. It has been effective against various species of coccidia, including those causing infections in poultry, swine, and other livestock.
Antimicrobial Properties: Carbarsone has also exhibited antimicrobial activity against certain bacteria and fungi. It has been used in animal feed as a growth promoter and for the prevention of bacterial and fungal infections in livestock. However, its use as an antimicrobial agent has been largely discontinued due to concerns about antibiotic resistance and environmental contamination.
Arsenic Toxicity: Carbarsone contains arsenic, a toxic heavy metal that can accumulate in the environment and pose risks to human health and ecosystems. Chronic exposure to arsenic has been associated with various adverse health effects, including skin lesions, cardiovascular diseases, neurotoxicity, developmental abnormalities, and increased cancer risk. Therefore, the use of carbarsone and other arsenic-containing compounds has been restricted or banned in many countries to protect public health and the environment.
Regulatory Status: Carbarsone and related compounds have been phased out or banned in many countries due to concerns about arsenic toxicity and environmental contamination. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have imposed restrictions on the use of arsenic-containing compounds in food production and animal husbandry to minimize human exposure and environmental impact.
Alternatives: In light of the concerns associated with carbarsone and other arsenic-containing compounds, efforts have been made to identify safer and more sustainable alternatives for the prevention and treatment of parasitic infections in livestock. These alternatives may include the use of other antiparasitic drugs, vaccines, improved management practices, and biosecurity measures to reduce the risk of infection and transmission.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 1.5 | 0.3 | 4 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 1.3 | 0.5 | 1.6 |
| Allergies | 2.3 | 1.2 | 0.92 |
| Allergy to milk products | 0.8 | 1.2 | -0.5 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 1.6 | 3.2 | -1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.5 | 1 |
| Ankylosing spondylitis | 2.1 | 0.9 | 1.33 |
| Anorexia Nervosa | 0.7 | 1.9 | -1.71 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 2.7 | 1.4 | 0.93 |
| Atherosclerosis | 1.1 | 0.5 | 1.2 |
| Atrial fibrillation | 1.9 | 1.3 | 0.46 |
| Autism | 3.4 | 3.2 | 0.06 |
| Autoimmune Disease | 0.9 | 0.8 | 0.13 |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 1.5 | 1.4 | 0.07 |
| Brain Trauma | 0.3 | 1.4 | -3.67 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.3 | 0.8 | -1.67 |
| Carcinoma | 1.9 | 1 | 0.9 |
| Celiac Disease | 0.8 | 1.6 | -1 |
| Cerebral Palsy | 0.9 | 1.3 | -0.44 |
| Chronic Fatigue Syndrome | 2.7 | 1.4 | 0.93 |
| Chronic Kidney Disease | 1.5 | 0.9 | 0.67 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 1.1 | -1.2 |
| Chronic Urticaria (Hives) | 1.1 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.8 | 1 | -0.25 |
| Cognitive Function | 1 | 0.8 | 0.25 |
| Colorectal Cancer | 2.4 | 1.6 | 0.5 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.4 | 1.4 | 0 |
| COVID-19 | 3.3 | 3 | 0.1 |
| Crohn's Disease | 2.9 | 2.1 | 0.38 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | 1.3 | -0.63 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 0.8 | 1.1 | -0.38 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 4 | 3.5 | 0.14 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.9 | 0.3 | 2 |
| Endometriosis | 1.5 | 1.6 | -0.07 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.5 | 0.7 | 1.14 |
| erectile dysfunction | 0.9 | 0.3 | 2 |
| Fibromyalgia | 1.5 | 0.6 | 1.5 |
| Functional constipation / chronic idiopathic constipation | 2 | 1.6 | 0.25 |
| gallstone disease (gsd) | 1.5 | 0.8 | 0.88 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.4 | -0.33 |
| Generalized anxiety disorder | 1.5 | 0.6 | 1.5 |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 1.2 | 1.8 | -0.5 |
| Gulf War Syndrome | 0.1 | 0.3 | -2 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 1.9 | 0.9 | 1.11 |
| Heart Failure | 1.5 | 1.4 | 0.07 |
| Hidradenitis Suppurativa | 0.6 | 0.3 | 1 |
| High Histamine/low DAO | 0.7 | 0.6 | 0.17 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 0.9 | 0.7 | 0.29 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 1.9 | 1.8 | 0.06 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 1.3 | 0.3 | 3.33 |
| IgA nephropathy (IgAN) | 0.9 | 1.4 | -0.56 |
| Inflammatory Bowel Disease | 2.8 | 3.2 | -0.14 |
| Insomnia | 0.7 | 2.1 | -2 |
| Intelligence | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 2.7 | 2 | 0.35 |
| ischemic stroke | 1.5 | 1.7 | -0.13 |
| Liver Cirrhosis | 3.3 | 1.9 | 0.74 |
| Long COVID | 2.7 | 2.7 | 0 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.6 | 0.4 | 0.5 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.6 | 0 |
| ME/CFS with IBS | 0.7 | -0.7 | |
| ME/CFS without IBS | 0.9 | 0.6 | 0.5 |
| Menopause | 0 | 0.5 | 0 |
| Metabolic Syndrome | 2.6 | 2.3 | 0.13 |
| Mood Disorders | 3.9 | 3.8 | 0.03 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
| Multiple Sclerosis | 2.2 | 1.8 | 0.22 |
| Multiple system atrophy (MSA) | 0 | 0.7 | 0 |
| myasthenia gravis | 0.6 | 0.5 | 0.2 |
| neuropathic pain | 0.3 | 1.5 | -4 |
| Neuropathy (all types) | 0.4 | 1.1 | -1.75 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 2.1 | 0.19 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 3 | 3.1 | -0.03 |
| obsessive-compulsive disorder | 2.1 | 1 | 1.1 |
| Osteoarthritis | 1.2 | 0.9 | 0.33 |
| Osteoporosis | 2.3 | 0.4 | 4.75 |
| Parkinson's Disease | 2.6 | 3.6 | -0.38 |
| Polycystic ovary syndrome | 2.6 | 1.9 | 0.37 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | |
| primary biliary cholangitis | 0.3 | 0.3 | |
| Primary sclerosing cholangitis | 0.7 | 0.6 | 0.17 |
| Psoriasis | 1.2 | 0.9 | 0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 1.7 | 0.82 |
| Rosacea | 0.6 | 0.5 | 0.2 |
| Schizophrenia | 2 | 2.1 | -0.05 |
| scoliosis | 0.2 | 0.4 | -1 |
| Sjögren syndrome | 1.1 | 1 | 0.1 |
| Sleep Apnea | 1 | 1.6 | -0.6 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0 | 0 |
| Stress / posttraumatic stress disorder | 1.3 | 1.7 | -0.31 |
| Systemic Lupus Erythematosus | 1.6 | 1.8 | -0.13 |
| Tic Disorder | 0.3 | 0.3 | 0 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.6 | 2.1 | -0.31 |
| Type 2 Diabetes | 2.9 | 2.4 | 0.21 |
| Ulcerative colitis | 2.3 | 1.5 | 0.53 |
| Unhealthy Ageing | 0.9 | 0.9 | 0 |
| Vitiligo | 1.2 | 0.3 | 3 |
